Penn Medicine News Release
PHILADELPHIA – A novel therapy designed to attack tumors in patients
with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth
in 85 percent of advanced breast cancer patients treated in a small
study, researchers report in the July 6 issue of The Lancet.
“That is really an enormous response rate in a population of patients
who have received a median of three prior therapies,” says study
co-author Susan
M. Domchek, MD, associate professor of Medicine, University of Pennsylvania School of
Medicine, and director of the Cancer Risk Evaluation
Program at Penn’s Abramson Cancer Center... read more
Additional Information
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
